Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAFV600E inhibition and can be targeted to reduce resistance

[1]  S. Goodison,et al.  Chemokine (C-X-C) ligand 1 (CXCL1) protein expression is increased in aggressive bladder cancers , 2013, BMC Cancer.

[2]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[3]  G. Belbin,et al.  Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens , 2012, Cell Death and Disease.

[4]  Yunpeng Cai,et al.  A Candidate Molecular Biomarker Panel for the Detection of Bladder Cancer , 2012, Cancer Epidemiology, Biomarkers & Prevention.

[5]  S. Goodison,et al.  A Multi-Analyte Assay for the Non-Invasive Detection of Bladder Cancer , 2012, PloS one.

[6]  J. Chipuk,et al.  Examining BCL-2 family function with large unilamellar vesicles. , 2012, Journal of visualized experiments : JoVE.

[7]  S. Goodison,et al.  Influencing factors on the NMP-22 urine assay: an experimental model , 2012, BMC Urology.

[8]  K. Flaherty,et al.  Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Yu Shyr,et al.  Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. , 2012, The New England journal of medicine.

[10]  Tom Misteli,et al.  RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) , 2011, Nature.

[11]  J. Chipuk,et al.  Born to be Alive: A Role for the BCL-2 Family in Melanoma Tumor Cell Survival, Apoptosis, and Treatment , 2011, Front. Oncol..

[12]  Wengang Cao,et al.  Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. , 2011, Urologic oncology.

[13]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[14]  Emma R Cantwell-Dorris,et al.  BRAFV600E: Implications for Carcinogenesis and Molecular Therapy , 2011, Molecular Cancer Therapeutics.

[15]  N. Rosen,et al.  Mutant BRAF melanomas--dependence and resistance. , 2011, Cancer cell.

[16]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[17]  B. Taylor,et al.  The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner , 2010, Proceedings of the National Academy of Sciences.

[18]  C. Chuang,et al.  Profiling of matrix metalloproteinases and tissue inhibitors of metalloproteinases proteins in bladder urothelial carcinoma. , 2010, Oncology letters.

[19]  S. Whittaker,et al.  Gatekeeper Mutations Mediate Resistance to BRAF-Targeted Therapies , 2010, Science Translational Medicine.

[20]  Annelie Abrahamsson,et al.  Angiogenin Regulation by Estradiol in Breast Tissue: Tamoxifen Inhibits Angiogenin Nuclear Translocation and Antiangiogenin Therapy Reduces Breast Cancer Growth In vivo , 2010, Clinical Cancer Research.

[21]  Z. Werb,et al.  Matrix Metalloproteinases: Regulators of the Tumor Microenvironment , 2010, Cell.

[22]  D. Green,et al.  The BCL-2 family reunion. , 2010, Molecular cell.

[23]  R. Meacham,et al.  p38 mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion of bladder cancer by modulation of MMP-2 and MMP-9 activity. , 2010, Cancer research.

[24]  J. Settleman,et al.  Targeting the RAF-MEK-ERK pathway in cancer therapy. , 2009, Cancer letters.

[25]  Seamus J. Martin,et al.  Expression, purification and use of recombinant annexin V for the detection of apoptotic cells , 2009, Nature Protocols.

[26]  Wengang Cao,et al.  VEGF induces expression of Bcl-2 and multiple signaling factors in microvascular endothelial cells in a prostate cancer model , 2009, World Journal of Urology.

[27]  T. Kuwana,et al.  Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins , 2008, Proceedings of the National Academy of Sciences.

[28]  A. Strasser,et al.  Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. , 2008, The Journal of clinical investigation.

[29]  S. Fesik,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[30]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.

[31]  A. Letai,et al.  Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.

[32]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[33]  R. Marais,et al.  Melanoma biology and new targeted therapy , 2007, Nature.

[34]  S. Goodison,et al.  Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts , 2007, Molecular Cancer Therapeutics.

[35]  G. Hu,et al.  A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation , 2006, Proceedings of the National Academy of Sciences.

[36]  G. Lip,et al.  Angiogenin: a review of the pathophysiology and potential clinical applications , 2006, Journal of thrombosis and haemostasis : JTH.

[37]  M. Knowles.  Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese? , 2006, Carcinogenesis.

[38]  G. Hu,et al.  Neamine Inhibits Xenografic Human Tumor Growth and Angiogenesis in Athymic Mice , 2005, Clinical Cancer Research.

[39]  Liang Cheng,et al.  Elevated Expression of Angiogenin in Prostate Cancer and Its Precursors , 2005, Clinical Cancer Research.

[40]  M. Spitz,et al.  Increased plasma levels of angiogenin and the risk of bladder carcinoma , 2005 .

[41]  C. Bucana,et al.  Expression of interleukin‐8 gene in radical prostatectomy specimens is associated with advanced pathologic stage , 2005, The Prostate.

[42]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[43]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[44]  G. Hu,et al.  Angiogenin is translocated to the nucleus of HeLa cells and is involved in ribosomal RNA transcription and cell proliferation. , 2005, Cancer research.

[45]  P. Gontero*,et al.  Metastasis markers in bladder cancer: a review of the literature and clinical considerations. , 2004, European urology.

[46]  R. Takimoto,et al.  Increased expression of angiogenin in hepatocellular carcinoma in correlation with tumor vascularity. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Mason R. Mackey,et al.  Bid, Bax, and Lipids Cooperate to Form Supramolecular Openings in the Outer Mitochondrial Membrane , 2002, Cell.

[48]  S. Korsmeyer,et al.  Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. , 2002, Cancer cell.

[49]  J. Jenkins,et al.  A small-molecule inhibitor of the ribonucleolytic activity of human angiogenin that possesses antitumor activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[51]  J. Köllermann,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. , 2001, American journal of clinical pathology.

[52]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[53]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[54]  R Shapiro,et al.  Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: importance of inhibitor residues inside versus outside the C-terminal "hot spot". , 2000, Journal of molecular biology.

[55]  C. Dinney,et al.  Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  H. Miyake,et al.  Increased angiogenin expression in the tumor tissue and serum of urothelial carcinoma patients is related to disease progression and recurrence , 1999, Cancer.

[57]  E. Bröcker,et al.  Hypoxia-induced up-regulation of angiogenin in human malignant melanoma. , 1999, Cancer research.

[58]  B. Vallee,et al.  Chimeric anti-angiogenin antibody cAb 26-2F inhibits the formation of human breast cancer xenografts in athymic mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[59]  Y. Hsu,et al.  Nonionic Detergents Induce Dimerization among Members of the Bcl-2 Family* , 1997, The Journal of Biological Chemistry.

[60]  S. Groshen,et al.  Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. , 1997, Journal of the National Cancer Institute.

[61]  S. Fox,et al.  Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers. , 1996, Cancer research.

[62]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[63]  S. Groshen,et al.  Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. , 1995, Journal of the National Cancer Institute.

[64]  G. Hu,et al.  Angiogenin promotes invasiveness of cultured endothelial cells by stimulation of cell-associated proteolytic activities. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[65]  J. Riordan,et al.  Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[66]  G. Hu,et al.  Actin is a binding protein for angiogenin. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[67]  F Pozza,et al.  Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. , 1992, Journal of the National Cancer Institute.

[68]  G. Hu,et al.  An angiogenin-binding protein from endothelial cells. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Liotta,et al.  Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation , 1991, Cell.

[70]  B. Vallee,et al.  Characterization of ribonucleolytic activity of angiogenin towards tRNA. , 1989, Biochemical and biophysical research communications.

[71]  J. L. Bethune,et al.  Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. , 1985, Biochemistry.

[72]  L. Liotta,et al.  Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. , 1974, Cancer research.

[73]  Amy Young,et al.  Ras signaling and therapies. , 2009, Advances in cancer research.

[74]  A. Harris,et al.  Two mechanisms of basic fibroblast growth factor-induced angiogenesis in bladder cancer. , 1997, Cancer research.

[75]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[76]  M. Klagsbrun,et al.  Regulators of angiogenesis. , 1991, Annual review of physiology.

[77]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.